Supernus Pharmaceuticals
SUPN
272 hedge funds and large institutions have $1.71B invested in Supernus Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 92 increasing their positions, 99 reducing their positions, and 47 closing their positions.
18% more call options, than puts
Call options by funds: $11.5M | Put options by funds: $9.79M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.47% less ownership
Funds ownership: 101.44% → 100.97% (-0.47%)
7% less repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 99
6% less capital invested
Capital invested by funds: $1.81B → $1.71B (-$100M)
6% less funds holding
Funds holding: 289 → 272 (-17)
28% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$19.8M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$12M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$10.2M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$9.44M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$8.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$16.4M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$8.13M |
| 3 |
Capital Fund Management (CFM)
Paris,
France
|
-$7.96M |
| 4 |
Two Sigma Investments
New York
|
-$6.64M |
| 5 |
MFIMFI
Mesirow Financial Investment Management - Fixed Income
Chicago,
Illinois
|
-$5.74M |
SUPN Hedge Fund Activity: Q2 2019 in Review
272 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q2 2019, worth a combined $1.71B — down 5.5% from $1.81B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of SUPN and 34 opened new positions — a net loss of 13 holders — while 99 trimmed existing stakes and 92 added.
The largest buyer was Loomis, Sayles & Company, adding an estimated $19.8M. The largest seller was Invesco, cutting an estimated $16.4M.
- 272 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q2 2019, down from 289 in Q1 2019.
- Funds reported $1.71B of Supernus Pharmaceuticals stock for Q2 2019, down 5.5% quarter-over-quarter.
- 34 funds opened new Supernus Pharmaceuticals positions in Q2 2019 and 47 closed out, a net change of -13 holders.
- The largest Supernus Pharmaceuticals buyer in Q2 2019 was Loomis, Sayles & Company, an estimated $19.8M added.
- The largest Supernus Pharmaceuticals seller in Q2 2019 was Invesco, an estimated $16.4M sold.
Based on aggregated 13F filings for Q2 2019.